亚什兰(ASH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ASH 亚什兰

盘前交易 03-20 06:25:01 EDT

55.98

-0.35

-0.62%

盘前55.85

-0.13-0.23%

06:18 EDT

最高56.57	最低54.86	成交量79.84万
今开56.36	昨收56.33	日振幅3.03%
总市值26.41亿	流通市值26.10亿	总股本4,718万
成交额4,456万	换手率1.71%	流通股本4,662万
市净率1.02	ROE0.18%	每股收益-0.46
52周最高102.50	52周最低54.86	市盈率-122.08
股息1.60	股息收益率0.03	ROA1.94%

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ASH","market":"US","secType":"STK","nameCN":"亚什兰","latestPrice":55.98,"timestamp":1742414400000,"preClose":56.33,"halted":0,"volume":798356,"hourTrading":{"tag":"盘前","latestPrice":55.85,"preClose":55.98,"latestTime":"06:18 EDT","volume":43,"amount":2413.500001,"timestamp":1742465929737},"delay":0,"floatShares":46615360,"shares":47182862,"eps":-0.458541,"marketStatus":"盘前交易","change":-0.35,"latestTime":"03-20 06:24:55 EDT","open":56.36,"high":56.5656,"low":54.86,"amount":44564838.67056,"amplitude":0.030279,"askPrice":62.5,"askSize":40,"bidPrice":55,"bidSize":150,"shortable":3,"etf":0,"ttmEps":-0.458541,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1742477400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":55.98,"dividendRate":0.028582,"preHourTrading":{"tag":"盘前","latestPrice":55.85,"preClose":55.98,"latestTime":"06:18 EDT","volume":43,"amount":2413.500001,"timestamp":1742465929737},"postHourTrading":{"tag":"盘后","latestPrice":55.98,"preClose":55.98,"latestTime":"19:51 EDT","volume":32041,"amount":1793659.74,"timestamp":1742428294110},"volumeRatio":1.2454000805202297,"impliedVol":0.5948,"impliedVolPercentile":1},"requestUrl":"/m/hq/s/ASH","defaultTab":"news","newsList":[{"id":"2517921703","title":"Ashland Inc.盘中异动 临近收盘股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517921703","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517921703?lang=zh_cn&edition=full","pubTime":"2025-03-06 04:58","pubTimestamp":1741208297,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日04时58分，Ashland Inc.股票出现波动，股价大幅拉升5.01%。截至发稿，该股报59.44美元/股，成交量65.1707万股，换手率1.38%，振幅4.66%。Ashland Inc.股票所在的化学制品行业中，整体涨幅为2.95%。Ashland Inc.公司简介：亚什兰有限公司是一家全球性的特种材料公司，服务于广泛的工业市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306045818abea1d97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306045818abea1d97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2463526074.USD","BK4109","ASH"],"gpt_icon":0},{"id":"2517912504","title":"Seaport Global：下调Ashland(ASH.US)评级，由买入调整至中性评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517912504","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517912504?lang=zh_cn&edition=full","pubTime":"2025-03-05 21:41","pubTimestamp":1741182083,"startTime":"0","endTime":"0","summary":"Seaport Global：下调Ashland(ASH.US)评级，由买入调整至中性评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05214148547486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ASH"],"gpt_icon":0},{"id":"1140497084","title":"特朗普关税升级：摩根大通警告这些股票风险最大","url":"https://stock-news.laohu8.com/highlight/detail?id=1140497084","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140497084?lang=zh_cn&edition=full","pubTime":"2025-02-06 17:05","pubTimestamp":1738832725,"startTime":"0","endTime":"0","summary":"摩根大通表示，美国与主要贸易伙伴之间的贸易战，使得多家公司的前景充满不确定性。美国总统特朗普周末对加拿大和墨西哥的进口商品征收了 25% 的关税，并对中国商品加征 10% 的关税。然而，在周一，这些对加拿大和墨西哥的关税被暂缓 30 天，而中国则对部分美国商品进行最高 15% 的关税报复。为应对持续的“贸易动荡”，摩根大通策略师 Dubravko Lakos-Bujas 列出了一些美国公司，这些公司可能会受到美国对多个地区进口商品加征关税的影响。","market":"us","thumbnail":"https://community-static.tradeup.com/news/9a60a6e0acc961e4c8c72cb13fa65364","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/9a60a6e0acc961e4c8c72cb13fa65364"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"特朗普关税升级：摩根大通警告这些股票风险最大","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","MPC","EL","CL","APTV","PAG","FLNC","TSLA","PSX","AMZN","STZ","CMP","MOS","AAPL","NTR","UNP","JBL","CF"],"gpt_icon":1},{"id":"2508687974","title":"Ashland Inc.盘中异动 急速拉升5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508687974","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508687974?lang=zh_cn&edition=full","pubTime":"2025-02-04 23:17","pubTimestamp":1738682263,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日23时17分，Ashland Inc.股票出现异动，股价急速上涨5.01%。Ashland Inc.股票所在的化学制品行业中，整体涨幅为0.32%。其相关个股中，天美生物、艾仕得涂料系统、Ashland Inc.涨幅较大，Crown Electrokinetics Corp.、中北能、Senestech, Inc.较为活跃，换手率分别为12.35%、3.04%、0.98%，振幅较大的相关个股有Crown Electrokinetics Corp.、天美生物、中北能，振幅分别为11.64%、7.56%、6.24%。Ashland Inc.公司简介：亚什兰有限公司是一家全球性的特种材料公司，服务于广泛的工业市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204231743abc23192&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204231743abc23192&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ASH","BK4109","LU2463526074.USD"],"gpt_icon":0},{"id":"1172872816","title":"异动解读 | 亚什兰全线产品面临需求下滑 股价盘中大跌5.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172872816","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172872816?lang=zh_cn&edition=full","pubTime":"2025-01-30 00:44","pubTimestamp":1738169079,"startTime":"0","endTime":"0","summary":"亚什兰公司(ASH)股价今日盘中大跌5.8%,引发市场广泛关注。\n\n分析人士指出,亚什兰旗下产品线橡胶助剂、护发素和药品助剂等均面临需求下滑的压力,这可能是导致其股价暴跌的主要原因。与此同时,投资者也担心亚什兰产品毛利率可能会受到挤压。\n\n根据最新财报,亚什兰去年第四季度营收同比下滑8%,每股收益也低于分析师预期。公司表示,橡胶助剂等产品需求疲软是拖累业绩的主要因素。展望今年,亚什兰预计个人护理和中间体产品销售依然低迷。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 亚什兰全线产品面临需求下滑 股价盘中大跌5.8%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ASH"],"gpt_icon":0},{"id":"2507653635","title":"Ashland Inc.盘中异动 股价大跌5.02%报67.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507653635","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507653635?lang=zh_cn&edition=full","pubTime":"2025-01-30 00:11","pubTimestamp":1738167118,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日00时11分，Ashland Inc.股票出现波动，股价急速下跌5.02%。截至发稿，该股报67.59美元/股，成交量41.3371万股，换手率0.88%，振幅6.43%。Ashland Inc.股票所在的化学制品行业中，整体涨幅为0.11%。Ashland Inc.公司简介：亚什兰有限公司是一家全球性的特种材料公司，服务于广泛的工业市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501300011599613a24f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501300011599613a24f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2463526074.USD","ASH","BK4109"],"gpt_icon":0},{"id":"1156013890","title":"艾仕兰2025年第一季度调整后每股收益$0.28超出预期$0.18，销售额$4.05亿低于预期$4.2892亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1156013890","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156013890?lang=zh_cn&edition=full","pubTime":"2025-01-29 06:05","pubTimestamp":1738101934,"startTime":"0","endTime":"0","summary":"艾仕兰公司报告季度每股收益为$0.28，超出分析师一致预期的$0.18，超出幅度为55.56%。公司报告季度销售额为$4.05亿，低于分析师一致预期的$4.2892亿，差距为5.58%。这比去年同期的销售额$4.73亿下降了14.38%。以上内容来自Benzinga Earnings专栏，原文如下：Ashland  reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.18 by 55.56 percent. This is a 37.78 percent decrease over earnings of $0.45 per share from the same period last year.  The company reported quarterly sales of $405.00 million which missed the analyst consensus estimate of $428.92 million by 5.58","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"艾仕兰2025年第一季度调整后每股收益$0.28超出预期$0.18，销售额$4.05亿低于预期$4.2892亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH"],"gpt_icon":0},{"id":"2491680204","title":"基石药业-B现涨逾4% 将于ASH年会公布CS5001针对晚期淋巴瘤最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2491680204","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2491680204?lang=zh_cn&edition=full","pubTime":"2024-12-16 11:29","pubTimestamp":1734319740,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　基石药业-B（02616）早盘上涨3.80%，现报2.73港元，成交额1450.93万港元。\n　　近日，基石药业-B公布，将在第66届美国血液学会（ASH）年会上，公布管线2.0重磅产品CS5001（ROR1 ADC）针对淋巴瘤的最新临床数据。公告指出，CS5001是目前已知首个在实体瘤和淋巴瘤中均观察到临床疗效的ROR1 ADC。本次ASH年会的公布突出CS5001作为单药治疗晚期淋巴瘤的最新安全性和疗效数据。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-16/doc-inczrkux2813318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ASH","BK1574","LU2463526074.USD","02616","BK1161","BK4109"],"gpt_icon":0},{"id":"2491680666","title":"港股异动 | 基石药业-B(02616)涨超3% 将于ASH年会公布CS5001针对晚期淋巴瘤最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2491680666","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2491680666?lang=zh_cn&edition=full","pubTime":"2024-12-16 11:23","pubTimestamp":1734319420,"startTime":"0","endTime":"0","summary":"消息面上，近日，基石药业-B公布，将在第66届美国血液学会年会上，公布管线2.0重磅产品CS5001针对淋巴瘤的最新临床数据。公告指出，CS5001是目前已知首个在实体瘤和淋巴瘤中均观察到临床疗效的ROR1 ADC。本次ASH年会的公布突出CS5001作为单药治疗晚期淋巴瘤的最新安全性和疗效数据。另外，CS5001全球多中心临床试验目前仍在美国、澳洲和中国同步进行，目前剂量递增已完成，近期公司将启动涵盖多瘤种、具有注册潜力的Ib期剂量扩展研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","ASH","LU2463526074.USD","BK1161","BK4109","02616"],"gpt_icon":0},{"id":"2490879568","title":"港股异动 | 科济药业-B(02171)涨幅扩大至40% 公司在ASH年会上展示多项成果 通用型CAR-T早期数据优异","url":"https://stock-news.laohu8.com/highlight/detail?id=2490879568","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2490879568?lang=zh_cn&edition=full","pubTime":"2024-12-11 16:02","pubTimestamp":1733904155,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B尾盘涨幅扩大至40%，截至发稿，涨39.35%，报10.66港元，成交额6.47亿港元。国投证券指出，根据公司2024年ASH年会披露的同种异体CAR-T药物CT0590的早期临床数据，CT0590已显示出可控的安全性，并在多名患者中实现了深度和持久的临床缓解，其未来更多样本量的数据值得静待。此外，目前已有多个研究表明出CAR-T药物在自身免疫疾病显示出临床治愈的潜力，未来公司CAR-T产品在自身免疫疾病领域的应用值得静待。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4109","BK1587","BK4022","BK1574","02171","LU2463526074.USD","ASH","BK1161","CAR","BK4230","BK1585"],"gpt_icon":0},{"id":"2490600917","title":"港股异动 | 科济药业-B(02171)急升逾16% 公司在ASH年会展示赛恺泽、CT071和CT0590研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2490600917","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2490600917?lang=zh_cn&edition=full","pubTime":"2024-12-11 11:43","pubTimestamp":1733888619,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B急升逾16%，截至发稿，涨15.69%，报8.85港元，成交额1.26亿港元。消息面上，科济药业公布，CT0590、CT071和赛恺泽的更新结果已在第66届美国血液学会年会上进行报告。此外，公司此前公布，美国FDA已解除在美国的泽沃基奥仑赛注射液、舒瑞基奥仑赛注射液以及CT071的临床试验暂停。所述临床试验暂停与2023年12月FDA对公司位于北卡罗来纳州达勒姆的临床生产基地进行检查后发布的发现项有关。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223185.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2463526074.USD","BK1161","BK1585","BK1574","02171","BK1587","BK4109","ASH"],"gpt_icon":0},{"id":"2490098892","title":"ASH数据出炉：隐藏的ADC王者","url":"https://stock-news.laohu8.com/highlight/detail?id=2490098892","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2490098892?lang=zh_cn&edition=full","pubTime":"2024-12-10 17:58","pubTimestamp":1733824688,"startTime":"0","endTime":"0","summary":"在血液瘤领域，ADC的预期变得越来越明确。2023年销售额超过10亿美元的ADC中，辉瑞的Adcetris位居第二，罗氏的Polivy销售额也直逼10亿美元。复发是血液瘤难以逃脱的问题，而ADC与化疗、免疫治疗的机制并不相同，因此在血液瘤的后线治疗中仍能占据一席之地。另一方面，ADC还能成为前线疗法的有效手段。而在2024 ASH年会上，基石药业发布的CS5001最新临床数据，进一步引起了市场对于ROR1 ADC的关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/246622","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4231","LU2463526074.USD","ADC","BK4080","BK4109","ASH"],"gpt_icon":0},{"id":"2490940064","title":"金斯瑞生物科技(01548)：传奇生物宣布于2024年ASH年会上公布报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2490940064","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2490940064?lang=zh_cn&edition=full","pubTime":"2024-12-10 17:14","pubTimestamp":1733822078,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技 发布公告，于2024年12月10日，传奇生物科技股份有限公司已发布新闻稿，公布了3期研究CARTITUDE-4最新数据。MRD阴性率是多发性骨髓瘤患者生存期延长的重要预后标志。MRD阴性率的研究结果已在加利福尼亚州圣地牙哥举行的第66届美国血液学会年会暨展览会上以口头报告的形式发表。研究进行了随机分组，208名患者接受CARVYKTI治疗，211名患者接受标准疗法。截至目前，CARVYKTI已在全球五个国家推出，治疗患者人数逾4500名。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320223.HKD","LEGN","HK0000306701.USD","BK4139","HK0000320264.USD","BK4505","BK4588","ASH","HK0000306685.HKD","BK4109","LU2463526074.USD","BK1583","BK1576","BK4585","01548","BK1141"],"gpt_icon":0},{"id":"2490696260","title":"科济药业-B(02171)于2024年ASH年会上呈列的赛恺泽®、CT071 和CT0590的研究成果更新","url":"https://stock-news.laohu8.com/highlight/detail?id=2490696260","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2490696260?lang=zh_cn&edition=full","pubTime":"2024-12-10 16:32","pubTimestamp":1733819537,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B 公布，CT0590、CT071和赛恺泽 的更新结果已在第66届美国血液学会年会上进行报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222709.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1585","BK1574","02171","BK4109","LU2463526074.USD","BK1587","ASH","BK1161"],"gpt_icon":0},{"id":"2490864365","title":"2024 ASH | 与标准治疗相比，CARVYKTI® 显著提高了复发或难治性多发性骨髓瘤患者MRD阴性率","url":"https://stock-news.laohu8.com/highlight/detail?id=2490864365","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2490864365?lang=zh_cn&edition=full","pubTime":"2024-12-10 13:16","pubTimestamp":1733807760,"startTime":"0","endTime":"0","summary":"\" 3期研究CARTITUDE-4评估了CARVYKTI与PVd 或 DPd 的标准疗法在既往接受过一至三线治疗且来那度胺耐药的复发或难治性多发性骨髓瘤成人患者中的疗效。研究进行了随机分组，208名患者接受CARVYKTI治疗，211名患者接受标准治疗。此外，经CARVYKTI 治疗的患者迅速达到了较高的总体MRD阴性率，在第56天时，69%的可评估患者已达到MRD阴性。截至目前，我们已在全球五个国家推出了CARVYKTI，治疗患者人数逾4500名。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4576011_ZH76011_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["ASH","BK4585","LEGN","BK4588","BK4139","BK4505","LU2463526074.USD","BK4109"],"gpt_icon":0},{"id":"2490748167","title":"康诺亚-B(02162)：CM336 I/II期临床研究最新数据在第66届美国血液学会(ASH)年会上以壁报形式公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2490748167","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2490748167?lang=zh_cn&edition=full","pubTime":"2024-12-09 16:32","pubTimestamp":1733733168,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康诺亚-B 发布公告，其靶向BCMAxCD3的双特异性抗体CM336治疗复发或难治性多发性骨髓瘤的I/II期临床研究最新数据在第66届美国血液学会年会上以壁报形式公布。截至2024年10月30日，该研究共入组68例受试者。安全性评估显示，CM336安全性和耐受性良好。剂量成功递增至160 mg，且尚未达到最大耐受剂量。CM336在治疗复发或难治性多发性骨髓瘤受试者中表现出初步有效性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2463526074.USD","ASH","BK4109","BK1587","BK1161","02162","BK1574","BK1583"],"gpt_icon":0},{"id":"2490648977","title":"令人鼓舞的疗效和安全性 基石药业在ASH年会上公布CS5001针对晚期淋巴瘤的最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2490648977","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2490648977?lang=zh_cn&edition=full","pubTime":"2024-12-09 08:54","pubTimestamp":1733705682,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，12月9日，基石药业宣布，公司在第66届美国血液学会年会上公布管线2.0重磅产品CS5001针对淋巴瘤的最新临床数据。CS5001是目前已知首个在实体瘤和淋巴瘤中均观察到临床疗效的ROR1 ADC。CS5001全球多中心试验目前仍在美国、澳大利亚和中国同步进行，目前剂量递增已完成，近期我们将启动涵盖多瘤种、具有注册潜力的1b期剂量扩展研究。安全性数据剂量递增已完成，截至目前在10个剂量水平上均未报告DLT。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02616","ASH","BK1574","BK4109","LU2463526074.USD"],"gpt_icon":0},{"id":"2490769284","title":"和誉-B：和誉医药在ASH年会上展示匹米替尼治疗cGvHD的初步II期积极研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2490769284","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2490769284?lang=zh_cn&edition=full","pubTime":"2024-12-09 08:16","pubTimestamp":1733703360,"startTime":"0","endTime":"0","summary":"　　和誉-B发布公告，公司的附属公司上海和誉生物医药科技有限公司在第66届美国血液学会年会上以口头报告形式发布了匹米替尼治疗既往一线或多线治疗失败的慢性移植物抗宿主病患者的初步II期研究结果。尽管大多数入组患者尚未完成cGvHD缓解评估所需的6个月治疗周期，但是其中接受匹米替尼20毫克QD 治疗患者亚组的初步数据显示ORR已达64%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-12-09/doc-incyvhrw9800882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK4109","ASH","LU2488822045.USD","BK1161","159938","BK1574","LU2463526074.USD","02256","BK1515"],"gpt_icon":0},{"id":"2489738229","title":"和誉-B(02256)：和誉医药在第66届ASH年会上展示匹米替尼治疗cGvHD的初步II期积极研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2489738229","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2489738229?lang=zh_cn&edition=full","pubTime":"2024-12-08 19:19","pubTimestamp":1733656757,"startTime":"0","endTime":"0","summary":"尽管大多数入组患者尚未完成cGvHD缓解评估所需的6个月治疗周期，但是其中接受匹米替尼20毫克QD 治疗患者亚组的初步数据显示ORR已达64%。这些数据共同证明了匹米替尼治疗cGvHD相关的BOS的临床疗效。研究结果表明，匹米替尼在接受多种既往治疗的cGvHD患者中，表现出显著的临床疗效和良好的耐受性。基于最新的临床经验，匹米替尼可能为治疗cGvHD提供一种有前景的全新治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4109","02256","09939","LU2488822045.USD","159938","ASH","BK1161","LU2463526074.USD","BK1515","BK1574"],"gpt_icon":0},{"id":"2489885464","title":"港股异动 | 科济药业-B(02171)涨超5% 赛恺泽®、CT071和CT0590数据即将于2024年ASH年会上展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2489885464","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2489885464?lang=zh_cn&edition=full","pubTime":"2024-12-05 14:45","pubTimestamp":1733381117,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B涨超5%，截至发稿，涨5.75%，报6.8港元，成交额3279.07万港元。消息面上，科济药业此前宣布其产品赛恺泽、CT071和CT0590的数据将在第66届美国血液学会年会上以壁报形式展示，会议将于12月7日至10日举行。科济药业靶向BCMA的通用型CAR-T产品CT0590的首个人体一期试验中，共入组5名受试者，中位随访时间16.6个月。其中3例患者获得缓解，包括2例严格完全缓解和1例部分缓解。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1220733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2463526074.USD","BK1585","02171","BK4109","BK1587","BK1161","BK1574","ASH"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ashland.com","stockEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.1374},{"period":"3month","weight":-0.222},{"period":"6month","weight":-0.3589},{"period":"1year","weight":-0.4158},{"period":"ytd","weight":-0.2166}],"compareEarnings":[{"period":"1week","weight":0.0148},{"period":"1month","weight":-0.0698},{"period":"3month","weight":-0.0324},{"period":"6month","weight":-0.002},{"period":"1year","weight":0.0997},{"period":"ytd","weight":-0.0323}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ashland Inc.是特拉华州的一家公司。亚什兰是为广泛的消费和工业市场客户提供特种材料的全球领导者，包括粘合剂、建筑涂料、建筑、能源、食品和饮料、营养保健品、个人护理和制药。亚什兰为100多个国家的客户提供服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.003018},{"month":2,"riseRate":0.466667,"avgChangeRate":0.00131},{"month":3,"riseRate":0.622222,"avgChangeRate":0.037498},{"month":4,"riseRate":0.577778,"avgChangeRate":0.048415},{"month":5,"riseRate":0.622222,"avgChangeRate":0.022034},{"month":6,"riseRate":0.466667,"avgChangeRate":-0.00655},{"month":7,"riseRate":0.377778,"avgChangeRate":-0.007381},{"month":8,"riseRate":0.533333,"avgChangeRate":0.000964},{"month":9,"riseRate":0.4,"avgChangeRate":-0.014544},{"month":10,"riseRate":0.466667,"avgChangeRate":-0.006498},{"month":11,"riseRate":0.6,"avgChangeRate":0.008634},{"month":12,"riseRate":0.533333,"avgChangeRate":0.013505}],"exchange":"NYSE","name":"亚什兰","nameEN":"Ashland"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.7","shortVersion":"4.31.7","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚什兰(ASH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚什兰(ASH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚什兰,ASH,亚什兰股票,亚什兰股票老虎,亚什兰股票老虎国际,亚什兰行情,亚什兰股票行情,亚什兰股价,亚什兰股市,亚什兰股票价格,亚什兰股票交易,亚什兰股票购买,亚什兰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚什兰(ASH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚什兰(ASH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}